Drug-survival (DS) is a metric reflecting both efficacy and tolerability of treatments, 58
defined as the proportion of patients remaining on treatment over time1. We 59 conducted a
systematic review and meta-analysis to benchmark DS of biologics in 60 hidradenitis
suppurativa (HS), PROSPERO registration CRD42023443159. Further 61 details are
provided in the Supplementary Methods. 62 Seven studies were included (Figure S1),
reporting on DS in 1,170 patients–63 predominantly TNF-α inhibitors (n= 1,060; 91%) with …